Johnson & Johnson - Company Profile
Powered by 
All the data and insights you need on Johnson & Johnson in one report.
$295
- Save hours of research time and resources with
our up-to-date Johnson & Johnson Strategy Report
- Understand Johnson & Johnson position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Johnson & Johnson Regulatory Milestones
Track drug and patent expiries along with geographies impacted.
A sample of Johnson & Johnson Regulatory Milestones data
| Drug Name | Generic Name | Brand Name | Company Name | Expiry Geography | Constraining Patent Number | Constraining Patent Expiry | Drug Expiry (Estimated) | Highest Development Stage |
|---|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem | Lorem | Lorem | Pfizer Inc | Lorem | WXYZ | Lorem | Pending | Lorem |
| ketotifen fumarate | ketotifen fumarate | Acuvue Theravision With Ketotifen | Johnson & Johnson | Japan | JP5758074 | Mar-2027 | - | - |
| ketotifen fumarate | ketotifen fumarate | Acuvue Theravision With Ketotifen | Johnson & Johnson | EU | EP2079439 | Mar-2027 | - | - |
| Invega Hafyera | paliperidone palmitate | Invega Hafyera | Johnson & Johnson | United States | US11304951 | May-2041 | May-2041 | Marketed |
A sample of Johnson & Johnson Review Designation data
| Drug Name | Generic Name | Company Name | Indication | Geography | Designation Type | Designation Status | Designation Date |
|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | Lorem | Pfizer Inc | Lorem | Lorem | Lorem | Lorem | 29 Jun 2022 |
| paliperidone palmitate ER | paliperidone palmitate | Janssen Pharmaceuticals Inc | Schizophrenia | United States | Priority Review | Designated/Approved | 20 Jan 2015 |
| (daratumumab + hyaluronidase (human recombinant)) | (daratumumab + hyaluronidase (human recombinant)-fihj) | Janssen Inc | Amyloidosis | Japan | Orphan Drug Designation | Designated | 30 Oct 2020 |
| (daratumumab + hyaluronidase (human recombinant)) | (daratumumab + hyaluronidase (human recombinant)-fihj) | Janssen Biotech Inc | Amyloidosis | United States | Orphan Drug Designation | Designated/Approved | 08 Oct 2020 |
Feature
Regulatory Milestones provides an interactive, comprehensive, and analytical view of Drug and Constraining Patent Expiry and Exclusivity for Marketed and Pipeline (till preclinical development stage) pharmaceutical drugs in the United States (US), Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.
Benefit
Regulatory Milestones provides patent information for all novel Marketed and Pipeline pharmaceutical drugs available in the US, Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.
The Drug Expiry filters include Expiry Geography and Expiry Date as well as US-specific information.
The Drug Expiry date is based on the Constraining Patent Expiry, Patent Term Extension or Supplementary Protection Certificate (depending on the regulator), Exclusivity analysis and specific information on Review Designations granted by regulators.
US-specific information includes Exclusivity Type and Paragraph IV Certification filing under the Hatch Waxman Act (Paragraph IV).
Value
Regulatory Milestones is easily accessible and features a user-friendly platform. The tool includes attributes relating to Drug Expiry and Constraining Patents as well as attributes from Drugs and Companies .
Clients can utilize Regulatory Milestones to save time and effort through accumulated expiry information from various sources and registries in a standardized comparable format.
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward